Latest Headlines

Latest Headlines

Pfizer continues its deal spree with a $600M option pact to buy AM-Pharma

Continuing a deal spree aimed at beefing up a weak pipeline, Pfizer has agreed to pay $87.5 million for a stake in the Dutch biotech AM-Pharma along with an option to buy the biotech. And there's another $512.5 million on the table should Pfizer exercise its option, with the deal hinging on the biotech's successful completion of a Phase II study of a new treatment for acute kidney injury (AKI) related to sepsis.

UPDATED: Teva passed up an opportunity to buy Mylan target Perrigo: Globes

So far, Perrigo hasn't seemed too keen on selling itself to generics giant Mylan. It's rejected the U.S. drugmaker three times. But word has it that Perrigo tried to link arms with another generics giant on the block--and that's Mylan suitor Teva.

Mylan buy Teva? That's one way out of a sale, Chairman Coury says

Mylan Chairman Robert Coury has said more than once that Mylan isn't interested in selling itself to Teva. A deal for Mylan to buy its pursuer, though? That's a different story.

In a move toward an artificial pancreas, Debiotech gains option for Bayer's iSense CGM

Debiotech has gained an option with Oregon-based iSense CGM to acquire exclusive rights to use its continuous glucose monitoring technology with patch insulin pumps for diabetes treatment. The companies expect that the integration of Debiotech's Jewel Pump with the iSense continuous glucose monitor technology could lead to the creation of an accurate artificial pancreas--a device that continuously measures insulin levels and then automatically dispenses insulin accordingly in response.

'No path forward' with Teva, Mylan pledges amid warring roadshows

Late last month, Teva kicked off a roadshow to meet shareholders of its buyout target, Mylan, and find out what price it'll need to put forth to convince them to support a deal. As Mylan starts up its own roadshow, its message is clear: It's categorically opposed to a tie-up with the Israeli drugmaker, and investors can't force one, either.

MorphoSys bags a peptide biotech for $22M

MorphoSys pulled the trigger on a deal for partner Lanthio Pharma, paying €20 million ($22 million) for the shares it didn't already own and picking up a handful of peptide candidates.

Pharma dealmaking boosts M&A to record-setting heights in Q1

No surprise that the health industry is setting records, M&A-wise. According to PricewaterhouseCoopers, life sciences companies inked 35 deals worth $166.3 billion--more than all of 2014's transactions combined--in Q1.

Canadian CRO JSS buys its way into India with latest deal

Montreal-headquartered CRO JSS Medical Research is reaching into India, buying out Max Neeman International as it expands around the globe.

Gilead jumps into epigenetics with a bite-size biotech buyout

As market watchers wonder whether Gilead Sciences is on the verge of a blockbuster buyout, the Big Biotech inked a small deal that will beef up its efforts in the growing field of epigenetics.

UPDATED: Alexion scoops up a rare-disease blockbuster in $8.4B Synageva buyout

Alexion jumped into the M&A game today, striking a deal to acquire the rare-disease biotech Synageva for $8.4 billion in cash and stock in a deal that gives shareholders a big premium and the industry another example of the fast-rising valuations in the biotech world.